Bluebirdbio stock.

In the past week, BLUE stock has gone up by 13.41%, with a monthly gain of 42.79% and a quarterly surge of 17.39%. The volatility ratio for the week is 8.08%, and the volatility levels for the last 30 days are 9.74% for Bluebird bio Inc . The simple moving average for the past 20 […]

Bluebirdbio stock. Things To Know About Bluebirdbio stock.

Find real-time BLUE - bluebird bio Inc stock quotes, company profile, news and forecasts from CNN Business. Shares of bluebird bio (BLUE 2.64%) are down around 48% this year, but Wall Street analysts who follow the company expect better times ahead. The average price target on the stock implies a 99% gain.Dec 4, 2023 · Linda Haig. December 4, 2023. Company. Bluebird bio Inc (NASDAQ:BLUE) has a beta value of 1.00 and has seen 5.06 million shares traded in the last trading session. The company, currently valued at $465.79M, closed the last trade at $4.26 per share which meant it gained $0.44 on the day or 11.52% during that session. 13 thg 6, 2022 ... Bluebird Bio Stock Set for Largest One-Day Gain in Eight Years ... Bluebird Bio stock was flying high Monday after an advisory committee of the ...bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How. bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its …

You can submit queries to bluebird bio’s investor relations department by contacting 617-245-2107 or [email protected]. Show All Spinoff Stock Distribution

bluebird bio Inc (BLUE) stock is higher by 0.26% while the S&P 500 is down -0.11% as of 11:47 AM on Thursday, Nov 30. BLUE has risen $0.01 from the previous closing price of $3.86 on volume of 1,460,801 shares. Over the past year the S&P 500 is up 14.86% while BLUE is down -49.41%. BLUE lost -$0.74 per share in the over the last 12 …

Apr 6, 2023 · The case for buying the dip isn't exactly a slam dunk. With the stock down 52% in the last three months, Bluebird Bio ( BLUE -1.28%) shareholders are bound to be feeling pretty antsy. Between the ... [email protected]. Investor Contacts. Courtney O’Leary. Investor Relations (978) 621-7347. [email protected]. stock quote stock sub menu. Stock Quote; Stock Chart (Common Stock) Exchange (US Dollar) Price: Change (%) Volume: Today's Open: Previous Close: Intraday High: Intraday Low:Jul 12, 2023 · Curious what investors think of the latest price action? When the Bank of America upgraded its rating for Bluebird, the stock shot up from $3.13 to a high of $3.93, and today it closed at $3.51. Investors are ditching this gene therapy stock en masse, for good reason. The share price of bluebird bio ( BLUE -0.91%) is down a staggering 70% over the past year. The company has encountered ...

Get the latest bluebird bio, Inc. (BLUE) stock news and headlines to help you in your trading and investing decisions.

http://www.bluebirdbio.com. External link for bluebird bio. Industry: Biotechnology ... Stock. BLUE. December 2, 2023. NASDAQ. 20 minutes delay. $4.26. 0.44 ( ...

Nov 28, 2022 · bluebird bio has received approval for their first products and are on track to treat their first patient later this year. Find out why BLUE stock is a hold. Trading bluebird bio to $6: Bluebird bio (BLUE) is a biotech company focused on developing and commercializing gene and cell therapies to treat genetic diseases. Lead asset LentiGlobin (Zynteglo) is approved in US and Europe for the treatment of transfusion-dependent thalassemia. Bluebird's LentiGlobin (lovo-cel) is also in prBluebird bio (BLUE ...bluebird bio specializes in gene therapies for severe genetic diseases and has 2 FDA-approved products. EV/Sales multiple appears cheap. Find out why BLUE …bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock. SOMERVILLE, Mass. -- (BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per …Nov 28, 2022 · bluebird bio has received approval for their first products and are on track to treat their first patient later this year. Find out why BLUE stock is a hold. Bluebird Bio (BLUE 11.52%) and CRISPR Therapeutics (CRSP 2.88%) are two rising biotechs that specialize in gene-editing therapies to treat rare genetic blood disorders and cancer.

Once patients have the β A-T87Q-globin gene, their red blood cells (RBCs) can produce anti-sickling hemoglobin (HbA T87Q) that decreases the proportion of HbS, with the goal of reducing sickled RBCs, hemolysis, and other complications. bluebird bio’s clinical development program for lovo-cel includes the completed Phase 1/2 HGB-205 …- Commercial launch of ZYNTEGLO® (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 -- Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash - SOMERVILLE, Mass.--(BUSINESS WIRE)--Nov. 7, 2022-- bluebird …See bluebird bio, Inc. (BLUE) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock. (Business Wire) -17.24%. 09:12AM. Moderna Gets Good News, but Another Biotech Stock Is Falling Again.10 thg 3, 2021 ... BLUE Stock Pops On Gene Therapy Analysis ... On the stock market today, BLUE stock jumped 8.1% to 32.48. Bluebird uses an empty virus to deliver ...Find the latest bluebird bio, Inc. (BLUE) stock quote, history, news and other vital information to help you with your stock trading and investing. ... bluebird bio, Inc. …

Real time Bluebird Bio (BLUE) stock price quote, stock graph, news & analysis.

Nov 26, 2023 · Bluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share price if it lands this historic approval. View bluebird bio, Inc BLUE investment & stock information. Get the latest bluebird bio, Inc BLUE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of …As of September 4, 2023, Profund Advisors LLC has acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE), according to the latest Form 13F filing with the Securities & Exchange Commission. The firm reportedly purchased 297,018 shares of bluebird bio’s stock during the first quarter, with an estimated value of approximately $945,000.stock quote. Stock Quote. Stock Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed. Patients & Advocacy. Investors & Media. [email protected]. …If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

Nov 30, 2023 · bluebird bio Stock (NASDAQ: BLUE) stock price, news, charts, stock research, profile.

Find the latest 2seventy bio, Inc. (TSVT) stock quote, history, news and other vital information to help you with your stock trading and investing.

With the stock down 52% in the last three months, Bluebird Bio (BLUE-1.28%) shareholders are bound to be feeling pretty antsy. Between the company's weak cash position, missed deadline for a drug ...Earnings for bluebird bio are expected to decrease in the coming year, from ($1.81) to ($1.84) per share. bluebird bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next 30-90 days. Recent stocks from this report have soared up to +178.7% in 3 months - this month ...Apr 15, 2022 · With its shares down by around 84% in the past year, it's a wonder that investors are still interested in Bluebird Bio ( BLUE -4.44%) at all. It withdrew its beta thalassemia drug, Zynteglo, from ... Nov 4, 2023 · Bluebird Bio has experienced a barrage of issues in the past five years. The biotech has a potential approval on the way that could help it rebound. Even so, the company remains a risky stock to ... Another factor that may be contributing to BLUE stock gaining ground today — which jumped 17% and is up nearly 22% at time of writing — centers on possible short-squeeze speculation. According ...Conclusion - Streamlined and With 3 Shots at Approval In Next 12 Months bluebird Stock Looks Tempting. bluebird bio has experienced more than its fair share of setbacks - besides those discussed ...On May 9, bluebird bio will be reporting earnings Q1. Analysts are expecting losses per share of $0.370. Go here to follow bluebird bio stock price in real-time on Markets Insider.Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Between 2012 and 2021, FDA approved on average 44 drugs per year, skewed upwards by the 50+ annual tally between 2018 and 2021 (Fig. 1 ). Overall, it was a golden decade, with 445 new biologics ...See the latest bluebird bio Inc stock price (BLUE:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. bluebird bio, Inc. Common Stock (BLUE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global ... bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock. SOMERVILLE, Mass.-- (BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a publi... 11 months ago - Business Wire.bluebird bio Inc. Watch NEW Set a price target alert Open Last Updated: Nov 27, 2023 1:11 p.m. EST Real time quote $ 3.7650 -0.1250 -3.21% Previous Close $3.8900 Advanced Charting Volume: 2.77M... Instagram:https://instagram. cobra trading reviewbest high yield investmentsreviews of humana medicare advantage plansbest demo brokers mt4 Dec 4, 2023 · Linda Haig. December 4, 2023. Company. Bluebird bio Inc (NASDAQ:BLUE) has a beta value of 1.00 and has seen 5.06 million shares traded in the last trading session. The company, currently valued at $465.79M, closed the last trade at $4.26 per share which meant it gained $0.44 on the day or 11.52% during that session. In addition, bluebird bio, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). office real estate etfbest us broker for day trading View bluebird bio, Inc BLUE investment & stock information. Get the latest bluebird bio, Inc BLUE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. best banks for cash out refinance bluebird bio, Inc. Common Stock (BLUE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.BLUE Stock Overview · Revenue is forecast to grow 47.03% per year · Earnings have grown 18.9% per year over the past 5 years · Has less than 1 year of cash ...